Degradation Pathways of a Corticotropin-Releasing Factor Antagonist in Solution and Solid States

被引:3
|
作者
Badawy, S. [1 ]
Hussain, M. [1 ]
Zhao, F. [1 ]
Ye, Q. [1 ]
Huang, Y. [1 ]
Palaniswamy, V. [1 ]
机构
[1] Bristol Myers Squibb Co, Pharmaceut Dev, New Brunswick, NJ 08903 USA
关键词
chemical stability; stability; solid state stability; stabilization; solid dosage form; HYDROLYSIS;
D O I
10.1002/jps.21637
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Stability of the 1,3,5-triazine derivative (1), a corticotropin-releasing factor inhibitor, was studied in acidic solutions and in solid formulations. Degradant structures were elucidated using liquid chromatography/mass spectrometry (LC/MS) and nuclear magnetic resonance (NMR). Compound I was found to undergo hydrolysis via two pathways. Pathway 1 involves three hydrolysis steps of the triazine ring. Pathway 2 proceeds through hydroxy substitution of the amino group on the triazine ring followed by its hydrolysis, eventually resulting in the formation of the same degradant as pathway 1. Stability of 1 in the tablets was dependent on the manufacturing process and degradation appeared to proceed more rapidly in amorphous regions created during processing. Pathways 1 and 2 were observed in the tablets and degradation rate was enhanced at. high humidity condition. In addition to pathways I and 2, degradation in the tablet formulations was found to proceed through a third pathway involving nucleophilic displacement of the ether methoxy group by the triazine N-3. The resulting imidazolidinium intermediate was found to undergo a series of hydrolytic steps finally leading to the same end degradant as pathways 1 and 2. This intermediate was observed at a lower concentration in the tablet at the high humidity conditions and at very low concentrations in acidic solutions. (C) 2008 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 98:2636-2647, 2009
引用
收藏
页码:2636 / 2647
页数:12
相关论文
共 50 条
  • [31] THE PHYSIOLOGY OF CORTICOTROPIN-RELEASING FACTOR (CRF)
    RAUXDEMAY, MC
    GIRARD, F
    REPRODUCTION NUTRITION DEVELOPMENT, 1985, 25 (05): : 931 - 943
  • [32] CORTICOTROPIN-RELEASING FACTOR - PHARMACOKINETICS IN MAN
    SCHULTE, HM
    CHROUSOS, GP
    BOOTH, JD
    OLDFIELD, EH
    GOLD, PW
    CUTLER, GB
    LORIAUX, DL
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1984, 58 (01): : 192 - 196
  • [33] Corticotropin-releasing factor in antinociception and inflammation
    Schafer, M
    Mousa, SA
    Stein, C
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 323 (01) : 1 - 10
  • [34] Corticotropin-releasing factor, norepinephrine, and stress
    Koob, GF
    BIOLOGICAL PSYCHIATRY, 1999, 46 (09) : 1167 - 1180
  • [35] DESENSITIZATION OF CORTICOTROPIN-RELEASING FACTOR RECEPTORS
    REISINE, T
    HOFFMAN, A
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1983, 111 (03) : 919 - 925
  • [36] THE FUNCTIONAL NEUROANATOMY OF CORTICOTROPIN-RELEASING FACTOR
    SAWCHENKO, PE
    IMAKI, T
    POTTER, E
    KOVACS, K
    IMAKI, J
    VALE, W
    CIBA FOUNDATION SYMPOSIA, 1993, 172 : 5 - 29
  • [37] CORTICOTROPIN-RELEASING FACTOR (CRF) - A REVIEW
    EMERICSAUVAL, E
    PSYCHONEUROENDOCRINOLOGY, 1986, 11 (03) : 277 - 294
  • [38] Corticotropin-releasing factor, stress, and depression
    Heit, S
    Owens, MJ
    Plotsky, P
    Nemeroff, CB
    NEUROSCIENTIST, 1997, 3 (03): : 186 - 194
  • [39] Corticotropin-releasing factor receptor antagonists
    Gilligan, Paul J.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2006, 16 (07) : 913 - 924
  • [40] SECRETION OF CORTICOTROPIN-RELEASING FACTOR IN PREGNANCY
    SUDA, T
    IWASHITA, M
    TOZAWA, F
    USHIYAMA, T
    TOMORI, N
    SUMITOMO, T
    NAKAGAMI, Y
    DEMURA, H
    SHIZUME, K
    PROGRESS IN ENDOCRINOLOGY 1988, VOL 1 AND 2, 1988, 799 : 401 - 405